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Abstract
Group II metabotropic glutamate receptors (mGluRs) couple to the inhibitory G-protein Gi. The group II mGluRs
include two subtypes, mGlu2 and mGlu3, and their pharmacological activation produces analgesic effects in
inflammatory and neuropathic pain states. However, the specific contribution of each one of the two subtypes has
not been clarified due to the lack of selective orthosteric ligands that can discriminate between mGlu2 and mGlu3
subtypes.
In this study we used mGlu2 or mGlu3 knock-out mice to dissect the specific role for these two receptors in the
endogenous control of inflammatory pain and their specific contribution to the analgesic activity of mixed mGlu2/3
receptor agonists.
Our results showed that mGlu2
-/- mice display a significantly greater pain response compared to their wild type
littermates. Interestingly the increased pain sensitivity in mGlu2
-/- mice occurred only in the second phase of the
formalin test. No differences were observed in the first phase. In contrast, mGlu3
-/- mice did not significantly differ
from their wild type littermates in either phase of the formalin test.
When systemically injected, a single administration of the mGlu2/3 agonist, LY379268 (3 mg/kg, ip), showed a
significant reduction of both phases in wild-type mice and in mGlu3
-/- but not in mGlu2
-/- mice. However tolerance
to the analgesic effect of LY379268 (3 mg/kg, ip) in mGlu3
-/- mice developed following 5 consecutive days of
injection.
Taken together, these results demonstrate that: (i) mGlu2 receptors play a predominant role over mGlu3 receptors
in the control of inflammatory pain in mice; (ii) the analgesic activity of mixed mGlu2/3 agonists is entirely
mediated by the activation of the mGlu2 subtype and (iii) the development of tolerance to the analgesic effect of
mGlu2/3 agonists develops despite the lack of mGlu3 receptors.
Finding
Metabotropic glutamate (mGlu) receptors are consid-
ered promising targets in the treatment of chronic pain.
All mGlu receptor subtypes (mGlu1-8), except mGlu6,
are widely distributed along the pain neuraxis, and mod-
ulate cellular mechanisms of nociceptive sensitization
that underlie the development of chronic pain [1-3]. We
and others have focused on the role of group-II mGlu
receptors (mGlu2 and mGlu3), which are coupled to Gi
proteins and depress pain transmission at synapses
between primary afferent fibers and second order sen-
sory neurons in the dorsal horn of the spinal cord [4,5].
mGlu2/3 receptors are also found in peripheral nocicep-
tors, where their activation reduces hyperalgesia by lim-
iting cAMP-dependent regulation of TRPV1 channels
and TTX-resistant sodium channels [6-9]. The analgesic
role of mGlu2/3 receptors is supported by in vivo stu-
dies with LY354740, LY379268, and LY389795, which
activate both receptor subtypes with high potency and
are systemically active [10]. Systemic treatment with
these drugs causes analgesia in models of inflammatory
and neuropathic pain [11-13]. While activation of group
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individual role of mGlu2 and mGlu3 receptors in the
regulation of pain threshold has not been dissected, as
yet. This issue is relevant from a therapeutical stand-
point due to the increasing availability of allosteric
ligands that discriminate between the two receptor sub-
types [14].
In this study we used adult (7-8 weeks) male mGlu2
-/-
and mGlu3
-/- mice on a C57BL/6J background. mGlu2
-/-
mice were generated in the lab of Prof. Shigetada Naka-
nishi at Kyoto University, Japan. mGlu3
-/- mice were
purchased from Jackson Laboratories. Knockout mice
were backcrossed with C57BL/6J wildtype mice for the
generation of mGlu2
+/- and mGlu3
+/- mice. Knockout
mice and their wildtype littermates generated by hetero-
zygous crosses were used in our experiments. Mice were
housed 5 animals per cage with food and water ad libi-
tum in standard 12/12 h light/dark cycle, and were
manipulated daily for an adaptation period of 2 weeks
before testing. (1R,4R,5S,6R)-4-Amino-2-oxabicyclo
[3.1.0]hexane-4,6-dicarboxylic acid (LY379268; pur-
chased from Tocris Cookson) was dissolved in saline.
Different groups of mGlu2
-/- mice, mGlu3
-/- mice, and
their wild-type littermates (n = 8-12) were treated as fol-
lows: (i) acute injection of LY379268 (3 mg/kg, i.p.) or
saline 30 min prior to behavioral testing; (ii) repeated
injections of LY379268 (3 mg/kg, i.p. once daily for 5
days) or saline (only in mGlu3
-/- mice and their wild-
type littermates), with mice being tested 30 min after
the last injection. All experiments were carried out
according to the recommendations of Institutional Ani-
mal Care and Use Committee (IACUC). All efforts were
made to minimize animal suffering and to reduce the
number of animals used. Motor performance was
assessed on an accelerating rotarod treadmill (Ugo
Basile, Comerio, Italy) as described previously [15].
mGlu2
-/- and mGlu3
-/- mice did not show differences in
motor performance with respect to their wild-type litter-
mates on the rotarod test (Figure 1).
Inflammatory pain was assessed using the formalin
test. A 2% formalin solution (10 μl) was injected s.c.
into the plantar surface of the right hind paw. After the
injection, mice were immediately placed in a plexiglas
box (20 × 15 × 15 cm) surrounded by mirrors to allow
the observation of nociceptive responses that include
licking, lifting and shaking of the injected paw. Tests
were performed between 08:00 h and 12:00 h to mini-
mize variability. After formalin injection, mice were
observed for 1 h and their behaviors were recorded by
researchers blind to genotypes and drug treatments.
Formalin scores were separated into two phases, phase I
(0-10 min) and phase II (15-50 min). The mean beha-
vioral score was calculated in blocks of 5 min for each
of the two phases. A mean response was then calculated
for each phase.
We found no difference in the first phase of the for-
malin test between mGlu2
-/- and wild-type mice. In con-
trast, mGlu2
-/- mice showed a 4-fold increase in the
second phase of the formalin test as compared to wild-
type littermates (Figure 2A). Acute injection of
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Figure 1 Motor performance of mGlu2
-/- and mGlu3
-/- mice on the accelerating rotarod. (A) mGlu2
-/- mice and (B) mGlu3
-/- mice were
tested along with wild type littermates. Motor performance was tested by using the accelerating rotarod in five consecutive trials with 15 min
inter-trial interval. Results indicate the time (seconds) that mice remained on the rotating rod before falling. No differences were observed
between mGlu2
-/- mice or mGlu3
-/- mice and their respective wild-type littermates. p > 0.7 Two-way ANOVA followed by Fisher’s post hoc
analysis.
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Page 2 of 5LY379268 in wild-type mice caused analgesia in both
phases of the formalin test, as expected [16]. Remark-
ably, the drug was totally ineffective in mGlu2
-/- mice
(Figure 2A). In contrast to mice lacking mGlu2 recep-
tors, mGlu3
-/- mice did not show significant differences
in the first or second phase of the formalin test as com-
pared to their wild-type littermates (Figure 2B). In
mGlu3
-/- mice acute treatment with LY379268 caused
analgesia both in the first and second phases of the for-
malin test similar to that seen in wild-type mice (Figure
2B). Previous studies have shown that tolerance to
LY379268 develops following repeated dosing in rats
[13]. Thus we also examined whether tolerance to the
analgesic activity of LY379268 could be affected by a
lack of mGlu3 receptors (mGlu2
-/- mice were not tested
because they did not respond to LY379268). A 5-day
treatment with LY379268 failed to cause analgesia
in the first or second phase of the formalin test in
mGlu3
-/- mice (Figure 3), suggesting that tolerance
to the drug developed in spite of the lack of mGlu3
receptors.
Taken together, our data indicate that endogenous acti-
vation of mGlu2 receptors negatively regulate inflamma-
tory pain and mediate the analgesic response to dual
mGlu2/3 receptor agonists. These findings are in agree-
ment with the evidence that L-acetylcarnitine and histone
deacetylase inhibitors cause analgesia by up-regulating
the expression of mGlu2 receptors in the dorsal root
ganglia and spinal cord, without affecting the expression
of mGlu3 receptors [16-18]. A role for mGlu3 receptors
in pain has been suggested by studies showing an
i n c r e a s e de x p r e s s i o no fm G l u 3r e c e p t o rp r o t e i ni nt h e
cerebral cortex and spinal cord in response to peripheral
inflammation [19-21], and by the analgesic activity of spe-
cific inhibitors of N-acetylated-a-linked acidic dipeptidase
(NAALADase), the enzyme that degrades the putative
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Figure 2 The formalin test in mGlu2
-/- and mGlu3
-/- mice. A, Enhanced pain behavior in mGlu2
-/- mice after formalin injection. The first
phase (0 - 10 min) of pain behavior (defined as duration of licking responses) did not differ between mGlu2
+/+ mice and mGlu2
-/- mice after
formalin injection, but the second phase (10 - 50 min) was significantly enhanced in mGlu2
-/- mice. The acute injection of LY379268 (3 mg/kg
i.p.) 30 minutes before formalin injection significantly reduced both phases in mGlu2
+/+ mice but not in mGlu2
-/- mice. B, mGlu3
-/- mice did not
significantly differ from littermate mGlu3
+/+ mice in either of the two phases of the formalin test. The acute injection of LY379268 (3 mg/kg i.p.)
30 minutes before formalin injection elicited a significant reduction of both phases in mGlu3
+/+ mice and in mGlu3
-/- mice. Data represent the
mean ± S.E.M. of 8 to 12 mice per group. *p < 0.05 versus the respective vehicle group, ° p < 0.001 vs wild-type mice (two-way ANOVA)
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Figure 3 Loss of the analgesic effect of LY379268 in mGlu3
-/-
mice following repeated dosing. Vehicle or LY379268 (3 mg/kg,
i.p.) were injected for 4 days every 24 hours in mGlu3
-/- mice. On
day 5 vehicle or LY379268 were administered 30 min before
formalin injection. Data represent the mean ± S.E.M. of 8 to 12
mice. p > 0.3 vs vehicle group (t-test).
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(NAAG) [22-28]. However, the activity of NAAG at
mGlu3 receptors has recently been questioned [29].
The mechanisms underlying the selective involvement
of mGlu2 (vs. mGlu3) receptors in pain control remain
to be addressed. mGlu2 receptors are uniquely localized
in neurons and particularly in the pre-terminal region of
axons, where they negatively modulate neurotransmitter
release; in contrast, mGlu3 receptors are found in both
presynaptic and postsynaptic sites as well as in glial cells
[30]. Activation of glial mGlu3 receptors might stimulate
the production of neurotrophic factors, such as brain-
derived neurotrophic factor (BDNF) and nerve growth
factor (NGF) [31,32] that cause hyperalgesia and may
therefore counterbalance a potential analgesic effect of
mGlu3 receptors [33]. This interesting hypothesis war-
rants further investigation.
In conclusion we propose that: (i) mGlu2 receptors
play a predominant role over mGlu3 receptors in the
endogenous control of inflammatory pain and (ii) the
analgesic effects observed with the group II mGlu recep-
tor agonist LY379268 in the formalin test are mediated
by activity at mGlu2 and not mGlu3.
Our results are promising for a potential use of selec-
tive activators of mGlu2 receptors (e.g., mGlu2 receptor
enhancers) in pain treatment, providing that these drugs
show a favorable profile of tolerability in humans.
mGlu2
-/- mice show an impairment of hippocampal
mossy fibre long-term depression (LTD), although they
perform normally in water maze learning tasks [34].
Experiments combining the mGlu2/3 receptor agonist,
LY354740, and mGlu2
-/- mice show that activation of
mGlu2 receptors causes some cognitive impairment (i.e.
a deficit in delayed matching and non-matching to posi-
tion) and impairment in spatial learning [35]. However,
a 6-day treatment with the mGlu2/3 receptor antagonist,
(2S)-a-ethylglutamate, results in an impairment of long-
term (reference) memory in the eight-arm radial maze
[36], whereas no deficits in working memory are seen in
humans treated with LY354740 [37]. Therefore, it is not
entirely clear what side effect profile might be antici-
pated for mGlu2 modulators. Therefore, the potential
utility of mGlu2 receptor enhancers in the treatment of
chronic pain will be informed by data from clinical trials
with these drugs in the treatment of schizophrenia and
other disorders.
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